Newsbenzinga
AbbVie Reveals Positive Data for Eczema and Weight Loss Candidates
· Published
Article summary
AbbVie Inc. (NYSE:ABBV) announced clinical trial data on Wednesday for two pipeline candidates, highlighting progress in its immunology and metabolic disease portfolios. The pharma giant shared encouraging Phase 2
An excerpt from the original article.
Comments —
Loading comments…